Primex Pharmaceuticals Appoints Tomaso Dameno as Head of Operations
Mr. Dameno brings more than 15 years of experience in the pharmaceutical industry to Primex Pharmaceuticals. Most recently, he was Partner and Head of Global Pharma Compliance Operations at PQE Suisse. He has held various pharma line management roles at e.g. Zambon and Helsinn.
“I am excited to join Primex at this fast growth stage of its development and on the brink of such an important product launch on the pediatric anesthetic market. My extensive knowledge of the different aspects of the pharmaceutical business will help smooth the path to new markets,” says Tomaso Dameno.
Mr. Dameno’s key responsibilities are strategic and operative performance ensuring the development of the global supply chain, heading the regulatory, quality and pharmaceutical safety management functions, as well as contract manufacturing and logistics. He will be part of the Executive Team headed by CEO Kari Sarvanto in Zug, Switzerland.
Mr. Sarvanto comments: “I am pleased to see Primex is constantly able to attract top talent like Tomaso. The management is facing increasingly demanding challenges, not only due to the company’s fast growth, but also due to the exceptional novel anesthetic launch, as Primex aims to launch ADV6209 (OZALIN) in mere months.”
ADV6209 will be the first oral paediatric anaesthetic on the market in Europe, indicated for both premedication for anaesthesia and procedural sedation, and Primex is already preparing to launch it internationally, including the US market.
About Primex Pharmaceuticals
Primex Pharmaceuticals aims to become the leading global innovative anaesthesia company, and to expand in paediatric pharmaceuticals.
Primex brings a portfolio of strong, trusted anaesthesia products from propofol-based products acquired from Bayer, to a novel oral solution for paediatric procedural sedation, helping patients undergo a wide range of medical procedures. Primex Pharmaceuticals will continue to identify and acquire new medications that complete the range of products needed by the anaesthesiologists. Furthermore, the group includes a range of dental products and anaesthetics under the OGNA brand.
Primex Pharmaceuticals' global partner network operates in over 40 countries. The company is headquartered in Switzerland; all Primex products are manufactured in Europe. Primex Pharmaceuticals has proven underlying business operations and historical strong revenue growth.
See more at www.primexpharma.com
Primex Pharmaceuticals AG
Mr. Kari Sarvanto, Group CEO
Mobile: +41 796 162 694
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
NY-IFF15.2.2019 22:17:10 | Pressemeddelelse
IFF Recognized by SAM’s 2019 “Industry Mover” Sustainability Award
SFL15.2.2019 19:03:08 | Pressemeddelelse
SFL: strong financial position and results in 2018, consolidating the Group’s position as a prime player
NEW-WORLD-DEVELOPMENT15.2.2019 11:13:12 | Pressemeddelelse
5 Happening Cultural Destinations to Visit in 2019
ISAE-SUPAERO15.2.2019 10:38:10 | Pressemeddelelse
ISAE-SUPAERO Launches a New MOOC about Flight Mechanics
RED-REPLY15.2.2019 10:32:09 | Pressemeddelelse
REPLY: Red Reply Wins the Oracle “Partner of the Year Autonomous” Award
POSIFLEX-GROUP15.2.2019 09:02:04 | Pressemeddelelse
Posiflex showcases new Interactive Self-Service Kiosks and IoT Retail Product Innovations at EuroCIS 2019
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum